SigmaTron International, Inc. Reports Second Quarter Financial Results for Fiscal 2014
SigmaTron International, Inc. (SGMA), an electronic manufacturing services company, today reported revenues and earnings for the second quarter ended October 31, 2013.
Revenues increased to $56.6 million for the second quarter of fiscal 2014 from $52.7 million for the same quarter in the prior year. Net income increased to $784,654 in the second fiscal quarter compared to $482,834 for the same period in the prior year. Basic and diluted earnings per share were $0.20 and $0.19 respectively, for the quarter ended October 31, 2013, compared to basic and diluted earnings per share of $0.12 for the same quarter in fiscal 2013.
Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)
Echo to receive a $10 million cash investment from MTIA and Platinum Partners Company will withdraw the offering identified in recent Form S-1 filing Echo Therapeutics, Inc. (ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia (MTIA), Ltd., Hong Kong, for a license arrangement and equity investment in Echo.
1st Detect Awarded U.S. Patent for Novel Mass Spectrometer Design
1st Detect Corporation, a subsidiary of Astrotech Corporation (ASTC), announced today that the United States Patent Office ("USPTO") has allowed the issuance of a key patent for the company's unique ion trap used for chemical analysis and detection. "We are extremely pleased that the USPTO has allowed this patent. This patent is an important component of our intellectual property portfolio as it allows 1st Detect to enhance the performance of miniaturized mass spectrometers without an increase in size or cost," said Thomas B Pickens III, Chairman and CEO of 1st Detect. "The patent clearly validates our technology, while both demonstrating and protecting the progress we have made in the development of the 1st Detect mass spectrometer."
BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test
BG Medicine, Inc. (BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT(R) Code 82777) at the amount of a crosswalked test (analyte-specific CPT(R) Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.
"We are very pleased that CMS has finalized the previously announced preliminary determination of the Medicare reimbursement rate for our galectin-3 test," said Dr. Paul R. Sohmer, President and Chief Executive Officer of BG Medicine.
CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable soft tissue sarcomas (STS). Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3½ to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone.
Hanwha SolarOne Completes Two Module Supply Contracts Totaling 50 MW with China Huaneng Group
Hanwha SolarOne Co. Ltd. (the "Company", or "Hanwha SolarOne"), a top-10 global photovoltaic manufacturer of high-quality, cost-competitive solar modules, today announced it has supplied modules for two projects with an aggregate capacity of 50 MW to one of China's largest state-owned power companies, China Huaneng Group. The modules were delivered to two separate utility-scale installations: (i) an approximately 30 MW in Qingtongxia, a city in the Ningxia Hui Autonomous Region (NHAR) and (ii) a 20 MW project in Wuchuan, Inner Mongolia Autonomous Region.
NeuroMetrix to Partner with Omron Medical Devices for Distribution of NC-stat DPNCheck in China
NeuroMetrix, Inc. (NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, announced that it had entered into an agreement with Omron Medical Devices, a subsidiary of Omron Healthcare China, to be the exclusive distributor for NC-stat® DPNCheck® in China. Earlier this year NeuroMetrix and Omron Healthcare Co. Ltd. announced a partnership for the exclusive distribution of NC-stat DPNCheck in Japan.
NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test for early detection of diabetic peripheral neuropathy (DPN), which affects over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
Rambus and Micron Sign License Agreement
Agreement settles all outstanding disputes
Rambus Inc. (RMBS) and Micron Technology, Inc. (MU) today announced they have signed a broad patent cross license agreement. Under the agreement, Micron gains the right to use any Rambus patent for the manufacture of specified integrated circuit products, including any memory integrated circuit products. Certain of these memory products will enjoy a perpetual, paid-up license after the end of the initial term. The agreement requires quarterly royalty payments to Rambus over the next seven years capped at $10 million per quarter, with a rolling twelve-month cap fixed at $40 million, or $280 million during the initial term. In addition, Micron will have the option to extend the initial term of this agreement for additional renewal periods. As part of this agreement, the two companies have settled all outstanding patent and antitrust claims, and the agreement covers both Micron and Elpida products. Other terms and details of the agreement are confidential.
Double Eagle Petroleum Reports Cash Dividend on its Series A Cumulative Preferred Stock
Double Eagle Petroleum Co. (DBLE) reported today that its Board of Directors declared a cash dividend on its 9.25% Series A Cumulative Preferred Stock ("Series A Preferred Stock") in the amount of $0.578125 per share, payable on December 31, 2013 to shareholders of record as of December 20, 2013. The Series A Preferred Stock was issued on July 5, 2007 and trades on the NASDAQ Capital Market under the symbol "DBLEP."
Covidien Announces Definitive Agreement to Acquire Given Imaging
Advances Covidien strategy to more comprehensively address key specialties and procedures globally Adds Given Imaging’s broad suite of minimally invasive gastrointestinal diagnostic and monitoring solutions Accelerates development of world-class gastrointestinal portfolio focused on serving patient from diagnosis to treatment Accretive to earnings per share beginning in fiscal 2015
Covidien plc (COV) and Given Imaging Ltd. (GIVN) today announced a definitive agreement under which Covidien will acquire all of the outstanding shares of Given Imaging for $30.00 per share in cash, for a total of approximately $860 million, net of cash and investments acquired. This transaction provides Covidien additional scale and scope to serve the multibillion dollar global gastrointestinal (GI) market and supports the Company’s strategy to comprehensively address key global specialties and procedures.
Prana Completes PBT2 Dosing in IMAGINE Alzheimer's Disease Clinical Trial
95% Patient Retention Level Achieved in IMAGINE Trial
Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN), a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease (AD) clinical trial.
There were 42 patients with prodromal or mild AD enrolled in the Phase II double-blind placebo-controlled clinical trial of Prana's novel drug, PBT2. A total of 40 patients completed the planned 12 months of treatment with PBT2, or placebo, bringing the treatment phase of the trial to a close.
Food Technology Service, Inc. to Be Acquired by Sterigenics International LLC for $7.23 Per Share in Cash
Food Technology Service, Inc. (VIFL) (the “Company” or “FTSI”), a regional provider of sterilization services, announced today that it entered into a definitive merger agreement, dated December 5, 2013, under which the Company will be acquired by an affiliate of Sterigenics International LLC (“Sterigenics”), a portfolio company of GTCR, LLC. Under the terms of the merger agreement, upon completion of the transaction, the shareholders of the Company (other than holders of excluded shares and dissenting shares, as described in the merger agreement) will receive $7.23 per share in cash. The purchase price represents a premium of 28.4% over the Company’s closing share price on December 5, 2013 and a premium of 27.2% over the Company’s average closing share price for the 30 trading days ending on December 5, 2013.
Ballard Signs MOU with Van Hool for Further Zero Emission Fuel Cell Bus Deployments
Ballard Power Systems (NASDAQ:BLDP )(TSX:BLD.TO) has announced the signing of a non-binding Memorandum of Understanding (MOU) with Van Hool NV, Europe's fourth largest bus manufacturer, in support of the manufacture and further deployment of zero emission fuel cell buses.
By February 2014 the companies plan to jointly respond to last week's call for proposals under the EU Hydrogen Fuel Cell Joint Undertaking, and also plan to jointly respond to other future calls for proposals under the Horizon 2020 program.
Capstone Receives Multiple Orders for Offshore Platforms from New Alaska Distributor Chenega Energy
Capstone Turbine Corporation (www.capstoneturbine.com) (CPST), the world's leading clean technology manufacturer of microturbine energy systems, today announced that it received multiple orders for oil and gas offshore platforms from its new Alaskan distributor Chenega Energy LLC. The orders are for a single C1000 and multiple C200s for use on offshore platforms in Alaska's Cook Inlet.
Chenega Energy secured the orders from Hilcorp Alaska LLC, which purchased 10 oilrigs in Alaska's Cook Inlet from Chevron and Marathon Oil in 2012 and 2013. Since January 2012, oil production on the platforms has increased by 36 percent to approximately 9,700 barrels per day. Despite this increase, cost of oil production remains high and Hilcorp plans to invest over $500 million to further develop this project and make structural changes to help drive down costs.
The Medicines Company Acquires Rempex Pharmaceuticals
Novel Portfolio of Gram-Negative Antibiotics in Development Added to The Medicines Company's Infectious Disease Hospital Care Franchise The Medicines Company (NASDAQ: MDCO) today announced that it has acquired Rempex Pharmaceuticals, Inc., a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria.
Clive Meanwell, MD, PhD, Chairman and Chief Executive Officer of The Medicines Company, said, "Acute and intensive care hospitals around the world face rapid and increasing antibacterial resistance, especially to gram-negative pathogens. The assets of Rempex, particularly Carbavance™, will allow us to intensify our efforts to save lives, alleviate suffering and contribute to the economics of healthcare by serving leading hospitals."
ARCA biopharma Announces US FDA Acceptance of Gencaro IND Application for the Treatment of Atrial Fibrillation
Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company’s GencaroTM Investigational New Drug (IND) application for atrial fibrillation (AF) has been accepted by the U.S. Food and Drug Administration (FDA) and is now active.
Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R) Scar Management HydroGel
Oculus U.S Dermatology Partner, Quinnova Pharmaceuticals, Targeting U.S. Launch in Q2 2014
U.S. Double-Blind, Randomized Study for Scar Management Establishes Strong Foundation for International Approval
Oculus Innovative Sciences, Inc. (OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 27 countries, today announced that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Microcyn(R) Scar Management HydroGel.
Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis
Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA's Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
Celgene Invests in OncoMed's Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and Profit-Sharing Rights
OncoMed to Receive $177.25 Million Upfront, Including a $22.25 Million Equity Investment
OncoMed Pharmaceuticals, Inc. (OMED) and Celgene Corporation (CELG) today announced an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).
ICU Medical Receives Premier Inc. Contract for the New Diana™ Hazardous Drug Compounding System with Barcode Scanning
New Six-Year Agreement Marks the First GPO Contract for ICU Medical's Breakthrough Automated Sterile Compounding System for the Accurate, Safe, and Efficient Preparation of Hazardous Drugs, Set to Debut at ASHP Midyear in Orlando, December 8-12
ICU Medical Inc. (ICUI) today announced it has been awarded a six-year group purchasing contract from Premier Inc. for the DianaTM hazardous drug compounding system, the world's first user-controlled, automated sterile compounding system for the accurate, safe, and efficient preparation of hazardous drugs. Effective in 2014, this is the first time the Diana system, introduced in the United States in 2012, has been on contract with a group purchasing organization. A new version of the Diana system that incorporates a barcode scanning system will be debuted at the American Society of Hospital Pharmacists (ASHP) midyear clinical meeting in Orlando, FL, December 8-12, 2013.